POLD1 Mutations May be Effective Predictive Biomarker for the Response to Durvalumab plus Gemcitabine and Cisplatin in Metastatic Cholangiocarcinoma: A Case Report
Biliary tract cancers have a poor prognosis with limited treatment options. While immune checkpoint inhibitors have recently shown modest survival benefits as standard first-line therapy, reliable predictive biomarkers for the response to treatment remain lacking. This case report describes a 61-yea...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer Medknow Publications
2025-10-01
|
| Edice: | Journal of Cancer Research and Practice |
| Témata: | |
| On-line přístup: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-25-00028 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|